Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

John van der Valk Appointed MD of UBM Live Amsterdam

Published: Monday, December 23, 2013
Last Updated: Sunday, December 22, 2013
Bookmark and Share
Valk responsible for overseeing the company’s flagship brand CPhI.

UBM Live has announced the appointment of John van der Valk as the new Managing Director of the UBM Live Amsterdam business.

His responsibilities will include the management of the pharma portfolio including the Company’s flagship brand CPhI Worldwide, which continues to evolve as the leading pharmaceutical event globally.

As part of his new role, John is focusing on the integration of digital media within the live events portfolio. One example is the CPhI Online directory, which provides pharmaceutical buyer’s access to the CPhI database of the industry’s foremost suppliers, including a search function for individual services and products.

The ultimate goal is to make it easier for exhibitors to meet with international pharmaceutical companies, stay informed about the latest industry trends and remain ahead of a constantly changing pharmaceutical market.

John has over 15 years' experience within the events and media business, and comes to UBM Live from VNU. He has extensive knowledge of large-scale trade and consumer shows, digital marketing services, partner relationships and product development.

"I am delighted that John has joined the UBM Live team. John's experience and expertise is invaluable to his leadership of the Food and Pharma portfolios as we continue to focus on our customer's needs, and the deliverance of outstanding customer experience," stated Simon Foster, CEO of UBM Live.

Foster continued, "John's contributions to the UBM Live Board, and to our global collaborations for growth and development of the business, play a significant role."

Commenting on his appointment, John van der Valk remarked, "It is a really exciting time to be joining UBM Live as we build a global portfolio of industry leading pharma events. Working alongside Chris Kilbee, together we look forward to helping grow the pharma portfolio so that CPhI Worldwide and sister events continue to drive growth, partnerships and business across the pharma industry. Our aims for 2014 are to launch our events in new markets and to expand the scope of content we provide so that we can help industry stay in touch year round.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CPhI Report Highlights Acquisitions of Niche Technologies
Medium term prospects for contract services remain positive (both developed and emerging markets), despite fragmented biosimilar regulation and GDUFA fees.
Thursday, October 15, 2015
#CPhIChat Returns to CPhI Worldwide for the Second Successive Year
Pharma community is encouraged to lend their views on key industry issues.
Saturday, October 10, 2015
CPhI Experts Predict Continuous Manufacturing for All Within 10-years
Brian Carlin emphasizes need to build flexibility into design to manage impact of raw material variability through product lifecycle.
Thursday, October 01, 2015
CPhI & P-MEC China Closes as the Chinese Domestic Market Continues to Expand
International companies looking to gain a foothold in this lucrative and gentrifying pharma economy.
Tuesday, August 11, 2015
CPhI Korea Opens as South Korea Emerges as Global Leader in Biosimilar Trials
Government’s R&D strategy and “Pharma 2020 Vision” to see country as drug development leader.
Monday, July 27, 2015
CPhI Announces USA Market Report at InformEx
Country report to contain contrasting insights into the American pharma economy from European and domestic perspectives.
Wednesday, January 22, 2014
Chris Kilbee Appointed Group Director of UBM Pharma Portfolio
Kilbee responsible for driving the portfolio globally including increased emphasis on digital and content.
Monday, January 13, 2014
CPhI Japan 2014: Japanese Market to Continue to Dominate Global Pharma
Growth in the World’s second largest pharma region facilitated by innovation and loosened regulatory guidelines.
Monday, December 30, 2013
Rise of Generics and Patent Expirations Sees CPhI and P-MEC India 2013 Expand
Free online registration to attend CPhI and P-MEC India is now closed.
Tuesday, December 03, 2013
CPhI Worldwide 2013 Hosted More Than 34,000 Global Pharma Professionals
This year sees strong growth in APIs, biopharma, natural extracts, packaging and finished dosage with a highlight on innovation.
Tuesday, November 26, 2013
India Sets Ambitious Pharma Export Growth Targets
Indian generics exports growing at 24% per annum.
Monday, October 21, 2013
Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos